Clear Scientific, Inc.
Clinical-stage biopharmaceutical company developing highly selective small-molecule sequestrants to bind, inactivate, and accelerate clearance of toxic compounds. Focus areas include injectable and oral sequestrant therapeutics for acute intoxication (stimulants and opioids), preclinical and early-stage clinical development, analytical and formulation work, and collaborations with academic and clinical partners.
Industries
Nr. of Employees
small (1-50)
Clear Scientific, Inc.
55 Spinelli Place, Floor 3, Cambridge, MA 02138
Patents
Sequestration compounds for treatment of substance use disorder and uses thereof
US-12569478-B2
View Details
Sequestration compounds for treatment of substance use disorder and uses thereof
US-12569478-B2
View DetailsProducts
Injectable small-molecule sequestrant (lead clinical asset)
Injectable sequestrant formulation designed to bind intoxicants in blood and accelerate urinary clearance to rapidly reverse acute toxicity; progressed through Phase 1 and planned for Phase 2.
Oral sequestrant formulation (development-stage)
Orally delivered sequestrant designed to reduce gastrointestinal absorption of target compounds and limit brain exposure.
Injectable small-molecule sequestrant (lead clinical asset)
Injectable sequestrant formulation designed to bind intoxicants in blood and accelerate urinary clearance to rapidly reverse acute toxicity; progressed through Phase 1 and planned for Phase 2.
Oral sequestrant formulation (development-stage)
Orally delivered sequestrant designed to reduce gastrointestinal absorption of target compounds and limit brain exposure.
Expertise Areas
- Sequestrant-based therapeutic development
- Clinical trial management (early-stage)
- Analytical and bioanalytical method development
- Drug formulation and stability
Key Technologies
- Small-molecule sequestrants
- Injectable therapeutic formulations
- Oral sequestrant formulations
- HPLC
News & Updates
U.S. FDA granted Fast Track designation to the lead injectable small-molecule sequestrant for treatment of acute methamphetamine intoxication to facilitate development and expedite review.
Reported positive topline safety and tolerability data from a Phase 1 clinical trial for the lead injectable sequestrant.
Recipient of multiple grants from NIDA/NIH to support development of antidotes for fentanyl, methamphetamine, and mixtures including awards announced in 2020–2024.
U.S. FDA granted Fast Track designation to the lead injectable small-molecule sequestrant for treatment of acute methamphetamine intoxication to facilitate development and expedite review.
Reported positive topline safety and tolerability data from a Phase 1 clinical trial for the lead injectable sequestrant.
Recipient of multiple grants from NIDA/NIH to support development of antidotes for fentanyl, methamphetamine, and mixtures including awards announced in 2020–2024.